Leflunomide Tablet, Film Coated
Product Images NDC 50090-5992

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Leflunomide (NDC 50090-5992). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500905992)

Leflunomide 20 mg film-coated tablets label from A-S Medication Solutions. The label shows dosage strength, storage instructions to keep at 68 to 77 degrees Fahrenheit, protection from light, and package contains 30 tablets. The National Drug Code (NDC) is 50090-5992-0.*

FDA Label Image

Figure1 (Leflunomide Fig1)

A bar graph titled '% ACR 20 Responder at Endpoint' displaying the percentage of responders in three clinical trials with durations of 6 and 12 months. It compares Leflunomide, Methotrexate, Placebo, and Sulfasalazine response rates, with values ranging approximately from 18.6% to 56.6%. The graph visualizes the effectiveness of these treatments by trial and treatment type.*

FDA Label Image

Figure2 (Leflunomide Fig2)

A line graph titled 'Trial 1 ACR Responders Over Time' showing the percentage of responders over a 12-month period. The x-axis represents time in months (0, 3, 6, 9, 12), and the y-axis shows the percentage of responders from -10 to 70%. Three lines display results for three treatment groups: PL (placebo) marked with circles, MTX (methotrexate) marked with squares, and LEF (leflunomide) marked with triangles. Leflunomide shows the highest percentage of responders over time, followed by methotrexate and placebo. The note indicates data are analyzed using last observation carried forward method.*

FDA Label Image

Figure3 (Leflunomide Fig3)

A bar chart titled 'Change in Sharp Score' illustrating progression changes across three clinical trials of different durations (12 months, 6 months, and 12 months). It compares Leflunomide (L), Methotrexate (M), Sulfasalazine (S), and Placebo (P) groups, showing numerical values for progression or change under these categories.*

FDA Label Image

Figure4 (Leflunomide Fig4)

A bar chart titled 'Change in Functional Ability Measure' showing change over three clinical trials at 6 or 12 months. It compares treatment effects of Leflunomide (L), Methotrexate (M), Placebo (P), and Sulfasalazine (S) on functional ability using the HAQ Disability Index. Bars indicate levels of improvement or decline for each treatment across the trials.*

FDA Label Image

Structure (Leflunomide Str1)

Chemical structure diagram of leflunomide, showing its molecular components with a trifluoromethyl-substituted phenyl ring and an oxazole ring.*

FDA Label Image

Structure2 (Leflunomide Str2)

Chemical structure of teriflunomide (A77 1726) shown as a 2D molecular diagram with atoms and bonds, including a trifluoromethyl group (CF3) attached to a benzene ring, and functional groups such as amide, hydroxyl, methyl, and nitrile.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.